Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects

Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing minimal weight loss while others achieve substantial reductions, and side effects such as nausea or vomiting affecting patients inconsistently. Understanding the biological basis of this variability is critical to improving treatment selection and patient counseling, and new findings demonstrate genetic predictors linked to both weight-loss efficacy and the likelihood of adverse effects with GLP-1 therapies.

Researchers at 23andMe Research Institute, a nonprofit medical research organization, identified genetic contributors to GLP-1 treatment variability in a large genome-wide association study (GWAS) of 27,885 individuals who had used GLP-1 medications, with results published in Nature on April 8, 2026. The analysis integrated genetic markers with self-reported experiences from participants to uncover associations relevant to both efficacy and tolerability. The findings provide direct evidence that variation in the genes targeted by GLP-1 therapies helps explain why people respond differently.

The study pinpointed a missense variant in the GLP1R gene that is significantly associated with increased weight-loss efficacy on GLP-1 medications. Genetic variation in both GLP1R and GIPR was linked to nausea and vomiting while on therapy. Notably, the association between GIPR variation and these side effects appeared specific to tirzepatide users and was not observed with semaglutide.

Researchers incorporated the genetic associations into a broader model that also includes demographic and clinical factors, demonstrating the ability to stratify individuals by expected weight-loss efficacy and risk for certain side effects. Among 23andMe research participants, estimated weight loss ranged from 6% to 20% of starting weight, and the likelihood of nausea or vomiting ranged from 5% to 78%, depending on genetics and other factors. The organization also introduced a GLP-1 Medications: Weight Loss and Nausea report within its Total Health service, which provides clinician guidance and an interactive tool based on these findings.

These discoveries, according to the institution, lay the foundation for more personalized approaches to obesity treatment by linking molecular targets to clinical outcomes. The work emphasizes how combining large-scale genotyping with structured phenotype data can inform stratification for both therapeutic benefit and adverse-event risk.

"While there is high interest in GLP-1 medications, there is significant variation in how well they work for different people. The market is crowded with weight loss support and medications, but the approach to weight management is typically one of trial and error. This can lead people to leap into treatment with a high degree of uncertainty and unrealistic expectations about efficacy and possible side effects," said Dr. Noura Abul-Husn, MD, Ph.D., Chief Medical Officer at the 23andMe Research Institute. "We believe these reports are a step forward in meeting an unmet need for a more informed and personalized approach to weight management."

Related Links
23andMe Research Institute